Investigators determined that sunitinib treatment was also associated with a fall in plasma renin concentration and plasma renin activity, whereas plasma concentrations of aldosterone did not change; therefore, the possibility that mineralocorticoid-receptor activation plays a role in the development of hypertension cannot be excluded [48]. This evidence concerns the gene NR3C2 and hypertensive disorder.